Status:
UNKNOWN
Triple Therapy in Patients With Idiopathic Thrombocytopenic Purpura : What is Behind?
Lead Sponsor:
Assiut University
Conditions:
Idiopathic Thrombocytopenic Purpura
Eligibility:
All Genders
18-65 years
Phase:
NA
Brief Summary
Idiopathic thrombocytopenic purpura (ITP) is a benign hematological disorder characterized by isolated thrombocytopenia. Development of antiplatelet autoantibodies is the main pathogenetic mechanism i...
Detailed Description
Blood born viral hepatitis is a type of viral hepatitis that is usually transmitted with transfusion of blood and blood products. Accordingly patients with hematological disorders are at higher risk f...
Eligibility Criteria
Inclusion
- Normal healthy Egyptians on the age range from 18-85.
- Egyptian patients with ITP in age range from 18- 65 on high dose dexamethasone together with cyclosporin and rituximab .
- Egyptian patients with ITP in age range from 18- 65 on parenteral or oral steriods.
Exclusion
- Age less than 18 years old.
- Pregnancy
- Thrombocytopenia other than ITP.
- Patients with ITP but on other modalities of treatment.
- Patients with blood born viral hepatitis infection before treatment with high dose dexamethasone together with cyclosporin and rituximab
Key Trial Info
Start Date :
November 1 2019
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 1 2021
Estimated Enrollment :
180 Patients enrolled
Trial Details
Trial ID
NCT04128358
Start Date
November 1 2019
End Date
June 1 2021
Last Update
October 24 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Assiut University
Asyut, Egypt